ANTIHYPERTENSIVE EFFICACY OF OLMESARTAN MEDOXOMIL, A NEW ANGIOTENSIN II RECEPTOR ANTAGONIST, AS ASSESSED BY AMBULATORY BLOOD PRESSURE MEASUREMENTS

Olmesartan medoxomil is a new angiotensin II receptor blocker. In this randomized, double-blind, placebo-controlled study, the efficacy and safety of olmesartan medoxomil was assessed in 334 patients with moderate to severe essential hypertension. Patients were randomized to receive placebo; 5, 20,...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Российский кардиологический журнал
المؤلفون الرئيسيون: J. M. Neutel, W. J. Elliott, J. L. Izzo, C. L. Chen, H. N. Masonson
التنسيق: مقال
اللغة:الروسية
منشور في: «FIRMA «SILICEA» LLC 2011-04-01
الموضوعات:
moderate to severe essential hypertension
olmesartan medoxomil
antihypertensive efficacy
safety
24-hour ambulatory blood pressure monitoring
الوصول للمادة أونلاين:https://russjcardiol.elpub.ru/jour/article/view/1155

الانترنت

https://russjcardiol.elpub.ru/jour/article/view/1155

مواد مشابهة